| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017632989 |
| P356 | DOI | 10.1007/S11899-015-0279-9 |
| P698 | PubMed publication ID | 26285891 |
| P2093 | author name string | Nicolaus Kröger | |
| P2860 | cites work | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| Allogeneic bone marrow transplantation for primary myelofibrosis | Q33197751 | ||
| Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation | Q33366694 | ||
| Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic | Q33371553 | ||
| Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients | Q33392291 | ||
| Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). | Q33393151 | ||
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q33400683 | ||
| Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party o | Q33558748 | ||
| Outcome of transplantation for myelofibrosis | Q34015474 | ||
| Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 | ||
| MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis | Q34047897 | ||
| Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype | Q34089614 | ||
| Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation | Q34260505 | ||
| Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation | Q35157388 | ||
| Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. | Q35634902 | ||
| The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation | Q35849342 | ||
| Effects of spleen status on early outcomes after hematopoietic cell transplantation | Q36712192 | ||
| JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse | Q36805838 | ||
| The history of myeloproliferative disorders: before and after Dameshek | Q36946585 | ||
| HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide | Q37078261 | ||
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 | ||
| Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review | Q37218445 | ||
| Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. | Q37457111 | ||
| New mutations and pathogenesis of myeloproliferative neoplasms. | Q37886439 | ||
| Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors | Q38018908 | ||
| JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 | ||
| Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study | Q41560568 | ||
| The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. | Q43162409 | ||
| Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q43265365 | ||
| The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
| Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia | Q43904556 | ||
| Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. | Q44220338 | ||
| Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). | Q44707716 | ||
| Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting | Q45126468 | ||
| Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis | Q45278082 | ||
| Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis | Q46919614 | ||
| Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type | Q47174502 | ||
| Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. | Q50534892 | ||
| AML transformation in 56 patients with Ph- MPD in two well defined populations. | Q51663644 | ||
| JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. | Q51811978 | ||
| Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. | Q53094253 | ||
| Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. | Q53099028 | ||
| Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. | Q53136705 | ||
| Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. | Q53493942 | ||
| JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. | Q54374933 | ||
| Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. | Q54646707 | ||
| Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect | Q57787154 | ||
| The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients | Q58455624 | ||
| Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning | Q60710884 | ||
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | Q61050093 | ||
| Introduction to ‘A special spotlight review series on BCR–ABL-negative myeloproliferative neoplasms’ | Q64008498 | ||
| Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect | Q64019035 | ||
| Allogeneic bone marrow transplantation for primary myelofibrosis | Q69485405 | ||
| Stem cell transplantation for myelofibrosis: a report from two Canadian centers | Q73549313 | ||
| Myelofibrosis with myeloid metaplasia | Q73712758 | ||
| Allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q73812277 | ||
| Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resea | Q77363568 | ||
| Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice | Q78410479 | ||
| Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading | Q79426706 | ||
| Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia | Q79817900 | ||
| Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases | Q80607021 | ||
| Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia | Q81321013 | ||
| Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT | Q82452904 | ||
| A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis | Q83388958 | ||
| The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries | Q84065231 | ||
| Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis | Q84271207 | ||
| Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis | Q84552610 | ||
| Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly | Q85333882 | ||
| Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation | Q86623207 | ||
| CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies | Q86921175 | ||
| Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation | Q87247099 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis | Q88113626 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 344-350 | |
| P577 | publication date | 2015-08-19 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Current Challenges in Stem Cell Transplantation in Myelofibrosis | |
| P478 | volume | 10 |
Search more.